Gemini: The 1,25-dihydroxy Vitamin D Analogs with Two Side-Chains

Vitamin D

Volumn 2, Issue , 2005, Pages 1511-1524

  Usković, Milan R ^a   Maehr, Hubert ^b   Reddy, Satyanarayana G ^c   Li, Yan Chun ^d   Adorini, Luciano ^e   Holick, Michael F ^d,f,g  

^a Bioxell Inc   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c BROWN UNIVERSITY   (United States)

^d USAUniversity of Chicago ^*  (United States)

^e BioXell SpA   (Italy)

^f Section of Endocrinology Diabetes and Nutrition   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746624729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50089-9     Document Type: Chapter

References (37)

1. 3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 1995, 270:10551-10558.
2. 3 analogs and their 20-epi homologs with the vitamin D receptor. J Biol Chem 1997, 272:3336-3345.
3. Tocchini-Valentini G, Rochel N, Wurtz JM, Mitschler A, Moras D Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. PNAS 2001, 98:5491-5496.
4. Vaisanen S, Perakyla M, Karkkainen JI, Uskokovic MR, Carlberg C Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. Mol Pharm 2003, 63:1-8.
5. 3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med Chem 2000, 43:2719-2730.
6. Baggiolini EG, Iacobelli JA, Hennessy BM, Batcho AD, Sereno JF, Uskokovic MR Stereocontrolled total synthesis of 1α,25-dihydroxycholecalciferol and 1α,25-dihydroxyergocalciferol. J Org Chem 1986, 51:3098-3108.
7. 2 produced in rat kidney. Biochemistry 1986, 25:5328-5336.
8. 3. Biochemistry 1987, 26:324-331.
9. 3 through C-24 oxidation pathway. Biochemistry 1989, 28:1763-1769.
10. Li YC The renin-angiotensin system. Vitamin D 2004, Elsevier, San Diego. Second Edition. D. Feldman, F. Glorieu, J.W. Pike (Eds.).
11. August P Initial treatment of hypertension. N Engl J Med 2003, 348:610-617.
12. 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
13. Malluche HH, Mawad H, Koszewski NJ Update on vitamin D and its newer analogs: actions and rationale for treatment in chronic renal failure. Kidney Int 2002, 62:367-374.
14. Kokubu T, Ueda E, Fujimoto S, Hiwada K, Kato A Peptide inhibitors of the renin-angiotensin system. Nature 1968, 217:456-457.
15. Burton J, Cody RJ, Herd JA, Haber E Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 1980, 77:5476-5479.
16. 3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs 2002, 3:1458-1463.
17. Becker BN, Hullett DA, O'Herrin JK, Malin G, Sollinger HW, DeLuca H Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation 2002, 74:1204-1206.
18. 3 analogs as immunomodulatory agents. Trends Mol Med 2002, 8:174-179.
19. Griffin MD, Xing N, Kumar R Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003.
20. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T-cell activation. J Immunol 2000, 164:2405-2411.
21. 3 and mycophenolate mofetil treatment mediate transplantation tolerance 2001, 167:1945-1953.
22. 3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:6800-6805.
23. 3. Involvement of NF-kappaB down-regulation in transcriptional repression of the p40 gene. J Clin Invest 1998, 101:252-262.
24. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T-helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002, 195:603-616.
25. 3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1376.
26. 3 as dose-reducing agents for classical immunosuppressants. Transplantation 2000, 69:1932-1942.
27. 3, on bone reconstruction by vascularized bone allograft 2002, 30:422-427.
28. Corry RJ, Winn HJ, Russell PS Primarily vascularized allografts of hearts in mice. Transplantation 1973, 16:343-350.
29. Tanaka H, Abe E, Miyaura C, et al. 1,25-dihydroxycholeciferol and human myeloid leukemia cell line (HL-60): The presence of cytosol receptor and induction of differentiation. Biochem J 1982, 204:713-719.
30. Koeffler HP, Hirjik J, Iti L 1,25-dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985, 69:1399-1407. Southern California Leukemia Group.
31. Holick MF Vitamin D: A millennium perspective. J Cell Biochem 2003, 88:296-307.
32. 3 and its analogs in the treatment of psoriasis. Retinoids 1998, 14:12-17.
33. Bouillon R, Okamura WH, Norman AW Structure-function relationships in the vitamin D endocrine system. Endocrine Rev 1995, 16:200-257.
34. 2 in patients with hormone refractory prostate cancer. Clin Cancer Res 2002, 8:2820-2827.
35. Beer TM, et al. Weekly high-dose calcitriol and docetaxel in metastatic andorgen-independent prostate cancer. J Clin Oncol 2003, 21:123-128.
36. Zhao XY, Feldman D The role of vitamin D in prostate cancer. Steroids 2001, 66:293-300.
37. 3, DD-003. Cancer Res 1994, 54:5148-5153.